- The GAN_GRU factor is based on the GAN_GRU model, which utilizes a Generative Adversarial Network (GAN) for processing volume-price time series features and then uses a GRU model for time series feature encoding to derive the stock selection factor[4][13][14] - The GAN_GRU model includes two GRU layers (GRU(128, 128)) followed by an MLP (256, 64, 64), with the final output prediction return (pRet) used as the stock selection factor[22] - The GAN model consists of a generator and a discriminator. The generator aims to generate data that appears real, while the discriminator aims to distinguish between real and generated data. The generator's loss function is $L_{G} = -\mathbb{E}_{z\sim P_{z}(z)}[\log(D(G(z)))]$[23][24][25] - The discriminator's loss function is $L_{D} = -\mathbb{E}_{x\sim P_{data}(x)}[\log D(x)] - \mathbb{E}_{z\sim P_{z}(z)}[\log(1-D(G(z)))]$[27][28][29] - The GAN_GRU model's training process involves alternating training of the generator and discriminator until convergence[30] - The GAN_GRU factor's performance from January 2019 to September 2025 shows an IC mean of 0.1136, an annualized excess return of 22.58%, and a recent IC of 0.1053 as of September 28, 2025[41][42] - The GAN_GRU factor's IC mean for the past year is 0.0982, with the highest IC values in the coal, building materials, social services, non-bank finance, and food & beverage industries[42][44] - The top-performing long portfolios in September 2025, based on the GAN_GRU factor, include sectors like building materials, steel, social services, coal, and non-bank finance, with excess returns of 5.78%, 5.13%, 1.91%, 1.55%, and 1.21%, respectively[45] - Over the past year, the top-performing long portfolios based on the GAN_GRU factor include home appliances, building materials, food & beverage, utilities, and textiles & apparel, with average monthly excess returns of 5.04%, 4.96%, 3.92%, 3.53%, and 3.10%, respectively[46] - The top stocks in each industry based on the GAN_GRU factor as of September 28, 2025, include companies like Baolaite, Yutaiwei-U, Cangge Mining, Tuowei Information, Hengtong Co., Angang Co., and others[49][50]

Core Viewpoint - Baolait's stock price has shown a year-to-date increase of 29.59%, despite recent declines in the last five and twenty trading days, indicating volatility in its performance [2]. Company Overview - Baolait Medical Technology Co., Ltd. was established on June 28, 1993, and listed on July 19, 2011. The company is located in Zhuhai, Guangdong Province, and specializes in the research, production, sales, and service of medical device products [2]. - The main revenue composition of Baolait includes hemodialysis products (77.51%), monitoring devices (21.39%), and other products (1.10%) [2]. Financial Performance - For the first half of 2025, Baolait reported operating revenue of 523 million yuan, a year-on-year decrease of 2.43%. However, the net profit attributable to shareholders increased by 152.22% to 1.3134 million yuan [2]. - As of June 30, 2025, Baolait has distributed a total of 244 million yuan in dividends since its A-share listing, with 35.1578 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, Baolait had 18,400 shareholders, a decrease of 6.12% from the previous period. The average circulating shares per person increased by 6.50% to 11,477 shares [2]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund increased its holdings by 259,800 shares, while Hua Xia Zhong Zheng 500 Index Enhanced A became a new shareholder with 1,228,900 shares [3]. Market Activity - On September 24, Baolait's stock price rose by 2.03% to 8.54 yuan per share, with a trading volume of 21.1786 million yuan and a turnover rate of 1.19%. The total market capitalization reached 2.259 billion yuan [1]. - The net inflow of main funds was 1.2812 million yuan, with large single purchases accounting for 10.99% of the total, while sales accounted for 4.94% [1].

Core Points - Baolite announced that from September 10 to September 23, 2025, its stock closing price has been below 90% of the current conversion price (24.02 CNY/share) for 10 trading days, which may trigger the downward adjustment of the "Baolite Convertible Bonds" conversion price [2] Group 1 - The company is expected to follow the relevant regulations and agreements in the prospectus if the conversion price adjustment clause is triggered [2] - Investors are advised to pay attention to investment risks related to this potential adjustment [2]

证券代码：300246 证券简称：宝莱特 公告编号：2025-061 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于预计触发可转债转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、证券代码：300246，证券简称：宝莱特 2、债券代码：123065，债券简称：宝莱转债 3、转股价格：24.02 元/股 4、转股期限：2021 年 3 月 11 日至 2026 年 9 月 3 日 根据《广东宝莱特医用科技股份有限公司创业板向不特定对象发行可转换公 司债券募集说明书》（以下简称"《募集说明书》"）规定：在本次发行的可转 换公司债券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易 日的收盘价低于当期转股价格的90%时，公司董事会有权提出转股价格向下修正 方案并提交公司股东会表决。 2025年9月10日至2025年9月23日，公司股票已有10个交易日的收盘价格低于 当期转股价格（24.02元/股）的90%，预计可能触发"宝莱转债"转股价格向下修 正条件。若触发转股价格向下修正条款 ...

Core Viewpoint - Guangdong Baolait Medical Technology Co., Ltd. participated in the "2025 Guangdong Listed Companies Investor Online Reception Day" on September 19, 2025, to engage with investors and discuss company performance and future strategies [1]. Group 1: Financial Performance - In the first half of 2025, the subsidiary Suzhou Junkang reported a net profit of 6.70 million yuan, with an operating loss of 4.37 million yuan, and has been consolidated into the company's financial statements [1]. - For the first half of 2025, the net profit attributable to shareholders of the listed company was 1.31 million yuan, an increase of 152.22% year-on-year. The total assets at the end of the reporting period were 2.41 billion yuan, a decrease of 3.66% from the beginning of the year [1]. - The company's equity attributable to the parent company was 1.22 billion yuan, an increase of 0.25% from the beginning of the year. Cost reduction measures led to a decrease in expenses, but revenue and product profits declined due to price reductions in blood dialysis consumables and other factors [1]. Group 2: Business Strategy - The company focuses on two main business segments: "Life Information and Support" and "Renal Medical," aiming to become a leader in critical care and nephrology [1]. - In the Life Information and Support segment, the company emphasizes clinical needs, leveraging technological advancements to innovate and create differentiated solutions [1]. - In the Renal Medical segment, the company is developing differentiated consumables for hemodialysis and exploring technologies in peritoneal dialysis and CRRT, with plans to launch a CRRT machine integrated with overall solutions [1]. Group 3: Future Plans - The company is actively seeking related targets in the industry chain and will communicate investor suggestions to the board [1]. - The dialysis device production line project at Suzhou Junkang is expected to be operational by June 30, 2026, with an annual production capacity of 12 million dialysis devices [1]. - Due to strategic adjustments, the German subsidiary is currently undergoing asset disposal [1].

Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 52,343.60 million yuan, a year-on-year decrease of 2.43% [6] - The net profit attributable to shareholders was 131.34 million yuan, an increase of 152.22% year-on-year [6] - Total assets at the end of the reporting period were 240,748.13 million yuan, a decrease of 3.66% from the beginning of the period [6] - Equity attributable to shareholders increased by 0.25% to 122,170.35 million yuan [6] Group 2: Subsidiary Performance - The subsidiary Suzhou Jun Kang reported a net profit of 670.09 million yuan in the first half of 2025, but an operating loss of -436.95 million yuan [4] - The company plans to enhance product development and market expansion to achieve profitability for Suzhou Jun Kang [4] Group 3: Strategic Focus - The company is committed to its two main business segments: "Life Information and Support" and "Renal Medical" [2] - It aims to innovate and develop intelligent medical devices that address clinical pain points, transitioning from "functional integration" to "intelligent decision-making" [2] - The company is actively seeking related targets in the industry chain for potential acquisitions [3] Group 4: Future Plans - In 2025, the company will focus on high-end, intelligent, and IoT-enabled new products, while enhancing the penetration of high-margin products [8] - The company is leveraging opportunities from medical infrastructure expansion, hospital upgrades, and accelerated domestic substitution [8] - Plans include improving operational efficiency through lean management and cost reduction initiatives [8] Group 5: Project Developments - The Suzhou Jun Kang dialysis production line project is expected to produce 12 million dialysis devices annually, with completion targeted for June 30, 2026 [7] - The German subsidiary is undergoing asset management due to strategic adjustments [7]

证券日报网讯宝莱特9月22日在互动平台回答投资者提问时表示，截至2025年6月30日公司股东人数为 18，406户，最新的股东人数请关注公司定期报告。 （文章来源：证券日报） ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-060 债券代码：123065 债券简称：宝莱转债 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五） 15:30-17:00。届时公司部分董事、高级管理人员将在线就经营状况、公司治理、 发展战略等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃 参与！ 特此公告。 广东宝莱特医用科技股份有限公司 董事会 2025 年 9 月 17 日 广东宝莱特医用科技股份有限公司 关于参加 2025 年广东辖区投资者网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，广东宝莱特医用科技股份有限公司（以 下简称"公司"）将参加由广东证监局、广东上市公司协会联合举办的"向新提 质 价值领航——2025 年广东辖区上市公司投资者网上集体接待日"活动，现将 相关事项公告如下： ...

Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices. It is recognized as a "National Multi-parameter Monitor Industrialization Base" and a "National Manufacturing Single Champion Enterprise" [1][2]. - The company’s monitoring equipment is utilized in thousands of medical institutions across China [1]. Product Categories - The company offers a diverse range of monitoring products, including integrated monitors, modular monitors, and handheld monitors, as well as infusion pumps, ECG machines, and central monitoring systems [2]. - In the renal medical field, Baolait has a complete industrial chain with eight consumable bases and a channel platform, providing products for blood dialysis and peritoneal dialysis [2]. Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 523.44 million, a year-on-year decrease of 2.43%. However, the net profit attributable to shareholders increased by 152.22% to CNY 1.31 million [3]. - Total assets at the end of the reporting period were CNY 2.41 billion, a decrease of 3.66% from the beginning of the year [3]. R&D and Innovation - The company is focusing on clinical needs and technological innovation, aiming to integrate smart technology into product development to address core clinical pain points [4]. - Baolait's high-end monitoring products feature unique parameters and advanced technologies, enhancing their competitiveness in the market [5]. Market Demand and Opportunities - The number of blood dialysis patients in 2024 is projected to be 1.027 million, maintaining a compound annual growth rate of approximately 12% over the past decade [6]. - The company is actively expanding into the home dialysis market, particularly automated peritoneal dialysis, which has shown a growth rate of over 10% in recent years [7]. International Expansion - Baolait's blood dialysis products have begun to penetrate overseas markets, with a reported revenue growth of 121.29% in the first half of 2025 [8]. - The company is monitoring new policies related to blood dialysis and has developed products that meet the latest regulatory requirements [8]. New Product Launches - Recent product launches include peritoneal dialysis machines and smart monitoring devices, enhancing the company's product line in life information and support [8]. - The BioView C100 visual laryngoscope and S200 smart enteral nutrition pump were showcased at CMEF, featuring advanced imaging and safety features [8].

Group 1 - The core point of the article is that Baolait has announced the approval of the proposal to reappoint the accounting firm during its third extraordinary general meeting of shareholders in 2025 [2] Group 2 - The announcement was made on the evening of September 2 [2] - The proposal was part of the agenda for the extraordinary general meeting [2]